company? Let’s change
that.
Don't see your company?
Create a company profileMapping the immune system in unprecedented detail and scale. IMU’s discovery platform is building a new understanding of the immune system across health and disease, through next generation high resolution, systems-level immune profiling with AI and machine learning analytics
MultiplAI Health is a preventive medicine company pioneering blood screening for cardiovascular and other complex diseases. Powered by genomic RNAseq, proprietary data transformation, and comprehensive AI analysis, our test transforms a single blood sample into a precision, actionable risk assessment to drive proactive health management that will extend lifespan. We have a laboratory-validated prototype and are conducting our sixth clinical study to achieve technical validation of our whole-blood liquid biopsy approach in the cardiovascular space
Lyphe Group is UK’s medical cannabis pioneer, with vertical operations spanning product manufacturing, clinical care, pharmacy dispensing and doctor education. We are dedicated to bringing medical cannabis treatments to patients who need them through our operating companies - Lyphe Clinic, The Academy of Medical Cannabis, and Dispensary Green. Our family of companies encompass education for doctors, digital clinical care, manufacturing of cannabis medicines, and pharmacy home delivery direct to patients. Lead by the experts, guided by science and dedicated to improving people’s lives, The Lyphe Group is trusted by regulators, governments, the public and our partners to help patients across the world.
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Orri is a Specialist Eating Disorder Treatment service offering face-to-face and online treatment for those aged 16+ suffering with eating disorders and co-occurring conditions
We are Phlo, the Digital Pharmacy of the future. We deliver your NHS & Private prescriptions directly to you - when and where you need them. We put you in control: delivering one-off and repeat prescriptions. Our service is fast, secure, and fits around your day, so you can focus on what matters to you. Forget about pharmacy queues, traffic, medicine shortages, and never-ending stress. The future of pharmacy is today, join the movement!
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.
JUNE Medical Group is a women-owned medical devices company with offices in the UK, USA and Sweden. The company supplies selected products from leading manufacturers, and develops its own medical instruments, including the Galaxy II self retaining retractor – an extraordinary tool featuring the world’s first ever light attachment, Galaxy II™ LUX Approved Supplier: Galaxy II is already on the system in NHS Supply Chain, The Mount Sinai Hospitals, U.S. Department of Veterans Affairs approved (DAPA number is SP0200-21-H-0057) Circle Health Group, Baylor Scott & White Health The Queens Award for Enterprise: INNOVATION 2021 Women Owned Certified JUNE Medical incl Mosaic Surgical Manufacturing Most Trusted Surgical Medical Device Company 2022 - UK Best New Business 2015 UK Entrepreneur of the Year 2017 Growth Champion by Dept Int Trade 2019 Champions of Trade BAB /US Embassy UK 2021 UK CEO of the Year 2021
Grow Pharma is the leader in supplying unlicensed cannabis medicines in the UK. Grow Pharma was established by Grow Biotech and IPS Pharma, combining cannabis sector expertise with 18 years’ experience manufacturing and importing unlicensed medicines
Back in 2018, we realised there was a huge problem in the world of skincare: people don't just struggle with their skin – they struggle with how they're supposed to deal with it. With no truly effective solutions out there, low confidence levels and high frustrations make it difficult for us to bring our best selves to the day ahead. We knew there had to be a better way to give everyone's skin what it really needed. So, with a small (but growing) team of dermatologists, pharmacists, direct-to-consumer experts and other brilliantly innovative people, we decided to change the face of skincare. And so, here we are – on a mission to build an accessible way for people to tackle their skin goals once and for all, with powerful, personalised solutions that truly work. Start tackling your skin goals with our free online dermatology consultation and sign up with the code LINKEDIN23 to get your first Daily Doser for £4.99
Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing. Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians. Our Promise We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.
Order, track and get reminders for your NHS prescriptions – all in one place. Plus, get your medicine delivered to your door for free
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders
Cisiv’s technology platform is fit-for-purpose and enables Pharmaceutical and Medical Device companies to collect and manage safety and efficacy studies in the real world. Through our technology, organizations are able to expand their global reach and provide access to more patients. The platform, Baseline plus, spans every aspect of data collection and analysis as well as complex workflows for stakeholder engagement. This intuitive, modular web-based platform is highly configurable, providing unrivalled flexibility, no matter the scope or scale and has proven to reduce data management costs by 60%. Baseline Plus is an industry leading platform, including EDC, eConsent, ePRO, eCOA, eDiary, Surveys, Safety, e-Source, with functionality suitable for site-based, decentralized, and hybrid research. Currently, Cisiv’s intelligent platform is utilized by 90% of the top global pharmaceutical companies and has supported 200+ projects with pharma and biotech organizations.
We’re an innovative and forward-thinking Commercial Pharma analytics startup based in the UK. Since 2014 we’ve been focusing our efforts on providing cutting edge input to pharmaceutical organisations throughout Europe and North America. By combining years of experience in healthcare, pharmaceutical and data , we provide a powerful tool for acquiring real actionable insights to Commercial strategy, Formulary status, Salesforce effectiveness, targeting & segmentation, Sales analytics and many more.
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. We are building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Our technology is applicable across solid tumors and we are currently working on a pipeline of biomarker negative cancers, with triple negative breast cancer as the lead indication. Our team has experience in big pharma and R&D tools, and our medical advisory board includes oncologists from MD Anderson, Imperial College London, Stanford University Medical Center and UCSF.
Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere. With 46,000+ global team members, we have the opportunity to make a positive impact on healthcare in communities everywhere. Our team members are empowered to activate their careers through a collective of tools and resources designed to support individual career interests and aspirations. We value our listening culture that actions real outcomes and our team members appreciate and recognize one another for contributions that are making a meaningful global impact. No matter what your role is here, the work we do together has meaning. When you join our team, you become a crucial part of a greater purpose. We’re committed to supporting you personally and professionally, so we can achieve more together at the center of health.